Compare OSUR & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSUR | OABI |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | N/A | 89 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.1M | 225.9M |
| IPO Year | 2000 | N/A |
| Metric | OSUR | OABI |
|---|---|---|
| Price | $3.24 | $1.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.00 | ★ $4.50 |
| AVG Volume (30 Days) | ★ 460.6K | 340.0K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $167,064,000.00 | N/A |
| Revenue This Year | $4.48 | $52.42 |
| Revenue Next Year | $7.76 | $64.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.08 | $1.22 |
| 52 Week High | $3.76 | $2.22 |
| Indicator | OSUR | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 61.07 | 33.88 |
| Support Level | $3.10 | $1.32 |
| Resistance Level | $3.25 | $1.72 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 97.62 | 23.40 |
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.